WHO’s nOPV2 Prequalification Signals Progress in Global Vaccine Supply Resilience

Industry Insights from Next Move Strategy Consulting

In a significant advancement for global immunisation efforts, the World Health Organization (WHO) has granted prequalification to an additional novel oral polio vaccine type 2 (nOPV2), reinforcing the availability of vaccines critical to controlling poliovirus outbreaks. This milestone strengthens the global supply chain and supports ongoing initiatives aimed at interrupting virus transmission and advancing polio eradication. The newly approved vaccine is produced by Biological E. Limited in India using its own bulk production, following a technology transfer from PT Bio Farma (Persero) in Indonesia. This development builds upon WHO’s earlier emergency use listing and subsequent prequalification of nOPV2 vaccines manufactured and supplied through collaboration between these organizations. 

Strengthening Vaccine Manufacturing and Supply Resilience

WHO’s latest prequalification reflects continued efforts to expand and diversify the manufacturing base for quality-assured nOPV2 vaccines. By enabling additional production capabilities, the organization aims to enhance supply reliability and ensure countries have consistent access to vaccines during outbreak response situations. The nOPV2 vaccine was specifically developed to address outbreaks caused by circulating vaccine-derived poliovirus type 2 (cVDPV2), which can occur in populations with insufficient immunisation coverage. Compared with the traditional monovalent oral polio vaccine type 2, nOPV2 offers improved genetic stability, reducing the risk of triggering new outbreaks while maintaining its effectiveness in halting virus transmission.

Designed for Rapid and Broad Immunisation Response

The vaccine is authorised for outbreak response immunisation in populations at risk, particularly children, and is deployed rapidly when poliovirus outbreaks occur. Its use is guided by global health authorities, including the Global Polio Eradication Initiative (GPEI) and WHO, ensuring coordinated and timely response measures. Since its initial rollout, nOPV2 has been deployed extensively in outbreak settings, reaching hundreds of millions of children worldwide. These immunisation campaigns have played a measurable role in reducing transmission rates of poliovirus type 2 in affected regions, contributing to ongoing global eradication efforts.

Next Move Strategy Consulting’s Viewpoint

According to Next Move Strategy Consulting’s view, the WHO’s prequalification of Biological E. Limited’s nOPV2 Vaccine’s Market represents a strategically important advancement in strengthening the global polio eradication framework. By expanding the number of qualified manufacturers, the World Health Organization is reinforcing supply security and reducing reliance on limited production sources, which is essential for rapid and sustained outbreak response. The inclusion of Biological E. Limited as an independent bulk producer represents a critical step toward enhancing manufacturing self-reliance and ensuring consistent vaccine availability, particularly for countries facing urgent immunisation needs. This move also reflects the growing importance of technology transfer and regional production capabilities in strengthening global health preparedness.

Advancing Toward a Polio-Free Future

WHO’s latest prequalification underscores the importance of innovation, collaboration, and manufacturing expansion in combating infectious diseases. By enabling broader vaccine production and ensuring quality-assured supply, global health organizations are better equipped to contain outbreaks and accelerate progress toward complete polio eradication. This milestone reinforces the role of strategic partnerships and advanced vaccine development in safeguarding global public health and sustaining momentum in the fight against poliovirus.

Source: BioSpectrum Asia

Prepared by: Next Move Strategy Consulting